Vivani Medical, INC 8-K filings

Vivani Medical has successfully dosed all participants in its Phase 1 SLIM-1 trial for NPM-139, a long-acting semaglutide implant.

Vivani Medical announced an updated timeline for its SLIM-1 first dosing, now expected in August 2026, during a presentation at the Emerging Growth Conference.

Vivani Medical, Inc. announced a definitive agreement to merge its subsidiary Cortigent, Inc. with ClearOne, Inc., creating a combined entity with a focus on future growth.

Vivani Medical's 8-K filing details the approval of an amended stock incentive plan and regulatory clearance for a Phase 1 obesity drug trial.

Vivani Medical, Inc. announced its participation in the Jefferies Global Healthcare Conference on June 4, 2026, presenting a slide deck detailing its current status.

Vivani Medical reported first quarter 2026 financial results, highlighting the upcoming initiation of its Phase 1 SLIM-1 clinical trial for chronic weight management and a cash runway extending through the first half of 2027.

Vivani Medical announced successful preclinical data for its semaglutide implant NPM-139, plans for a Phase 1 study, and reported its Q4 and full-year 2025 financial results.

Vivani Medical, Inc. announced the pricing of a registered direct offering and concurrent private placement, raising approximately $4.5 million to fund research and development.

Vivani Medical reports Q3 2025 financial results, announces plans for Phase 1 semaglutide implant study in H1 2026, and secures $25.7 million in financing.

Vivani Medical, Inc. announced the pricing of a $15.7 million common stock offering and concurrent private placement to fund research and development and for general corporate purposes.

Vivani Medical, Inc. announced the temporary withdrawal of the record date for its Cortigent neuromodulation subsidiary spin-off due to U.S. federal government shutdown delays.

Vivani Medical, Inc. announced October 8, 2025, as the record date for the spin-off of its neuromodulation subsidiary, Cortigent, Inc., to shareholders.

Vivani Medical, Inc. filed an 8-K to provide an updated corporate slide presentation to the investment community.

Vivani Medical, Inc. announced plans to initiate a Phase 1 clinical study for its NPM-139 semaglutide implant for chronic weight management in the first half of 2026.

Vivani Medical, Inc. announced a $10 million equity financing to accelerate its semaglutide implant program, NPM-139, following positive preclinical and clinical data, alongside reporting Q2 2025 financial results and plans for a Cortigent spin-off.

Vivani Medical reports positive Phase 1 clinical data for NPM-115 and promising preclinical results for its prioritized semaglutide implant, NPM-139.

Vivani Medical, Inc. announced the successful outcome of its 2025 Annual Meeting of Stockholders, with all six director nominees elected, the independent auditor ratified, and executive compensation approved on an advisory basis.

Vivani Medical, Inc. announced preclinical data demonstrating an 82% reduction in liver fat and durable body weight effects in obese mice and rats using its exenatide implant with NanoPortal technology.

Vivani Medical, Inc. announced the appointment of Anthony Baldor, a finance veteran with over two decades of experience in the biotechnology sector, as its new Chief Financial Officer, succeeding Brigid Makes who is retiring.

Vivani Medical, Inc. has announced the filing of a Form 10 registration statement with the SEC for the planned spin-off of its wholly-owned subsidiary, Cortigent, Inc., aiming to create two independent, publicly traded companies by Q3 2025.

Vivani Medical announces a $3 million equity financing and reports first quarter 2025 financial results, highlighting progress in its LIBERATE-1 study and preclinical data for NPM-139.

Vivani Medical and Okava Pharmaceuticals are expanding their collaboration to develop OKV-119, a long-acting GLP-1 therapy, for weight management, diabetes, and other cardiometabolic conditions in dogs.

Vivani Medical reports successful initial administration and full enrollment in the LIBERATE-1 study, positive preclinical data for NPM-139, and secures $8.25M in equity financing.

Vivani Medical announces an $8.25 million private placement of common stock with an entity owned by its Board Chairman, Gregg Williams, to extend its cash runway and accelerate drug development.

Vivani Medical's NPM-139 semaglutide implant demonstrated nearly 20% placebo-adjusted weight loss in preclinical studies, suggesting potential for convenient once or twice-yearly dosing for chronic weight management.

Vivani Medical is spinning off its Cortigent neurostimulation business and has achieved the first implant and full enrollment in its LIBERATE-1 clinical trial for a GLP-1 implant.

Vivani Medical announced a $5 million equity financing, progress in its GLP-1 implant program, and reported third quarter 2024 financial results.

Vivani Medical will present its innovative drug implant technology at the Partnership Opportunities in Drug Delivery (PODD) Event and the ThinkEquity Conference in October 2024.

Vivani Medical has secured regulatory approval to begin its first human clinical trial in Australia for its GLP-1 (exenatide) implant designed for obesity and overweight management.

Vivani Medical, a biopharmaceutical company, will present at the Emerging Growth Conference on September 25, 2024, to discuss its long-acting drug implant technology.